Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2019

View Archived Issues

Fibroblasts specialize, too

Cracking influenza's egg code

CCR5 mutation leads to increased mortality

ECI-006 vaccine demonstrates promising safety and immunogenicity in patients with melanoma

First-in-human results presented for FPA-150 in patients with advanced solid tumors

MYLK genetic variant is associated with risk of pulmonary hypertension in sickle cell disease

Dosing initiated in phase I study of XmAb-22841 bispecific antibody

First patient dosed in phase III PEACE study of pegzilarginase in arginase 1 deficiency

BioInvent seeks IND clearance for phase I/IIa study of anti-FcgammaRllB antibody

Chinese researchers patent PI3K inhibitors

WntRx Pharmaceuticals identifies Wnt signaling inhibitors

Conditional European marketing authorization for Zynteglo for transfusion-dependent beta-thalassemia

Kissei Pharmaceutical describes CGRP receptor antagonists

Polish researchers identify 5-HT6 receptor antagonists

Jeil Pharmaceutical divulges new H+/K+-ATPase inhibitors

Kyowa Hakko Kirin initiates Japanese phase III trial of brodalumab in systemic sclerosis

Oligomerix continues NIH-funded work on tau oligomer inhibitor

First clinical data for Daiichi's IDH inhibitor DS-1001 presented for recurrent glioma

Phase III BLOCKSTONE study of Xofluza to prevent influenza infection meets primary endpoint

Qurient reports phase IIa data on telacebec for TB

FDA clears Nouscom's IND for phase I trial of NOUS-209 in MSI solid tumors

CEPI provides funding to support Themis' development of chikungunya vaccine MK-CHIK

Phase II trial of MD-7246 for IBS-D abdominal pain begins dosing

FDA approves Zerbaxa for hospital-acquired and ventilator-associated bacterial pneumonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...